The Lynx Group
Cholangiocarcinoma News

Toripalimab Combined with Gemcitabine and S-1 in the First-Line Treatment of Advanced BTCs

September 2022, Vol 3, No 3

Although gemcitabine plus platinum/fluorouracil combinations are the standard first-line treatment for advanced biliary tract cancers (BTCs), the overall outcomes are suboptimal. With the goal of improving survival outcomes, a single-arm, phase 2 study explored the safety and efficacy of the addition of anti–PD-1 inhibitor toripalimab to the standard chemotherapy (gemcitabine plus S-1 [tegafur, 5-chloro-2,4-dihydroxypyridine, and oxonic acid]) in the treatment of patients with previously untreated advanced BTCs.

Eligible patients received toripalimab plus chemotherapy (toripalimab 240 mg intravenously [IV], day 1; gemcitabine 1000 mg/m2 IV, days 1 and 8; S-1 40-60 mg orally twice daily, days 1-14 every 21 days). The primary end point was progression-free survival (PFS); secondary end points included overall survival (OS), objective response rate (ORR), and safety. An exploratory end point was the association between response with PD-L1 expression, tumor mutational burden (TMB), and genetic variations.

Between January 2019 and August 2020, a total of 50 eligible patients were enrolled in the study. The median age was 62 years; the majority were men (56%) with ECOG performance status of 1 (96%). Of these patients, 20 were diagnosed with intrahepatic cholangiocarcinoma, 20 with gallbladder cancer, and 10 with extrahepatic CCA. PD-L1 expression combined positive score (CPS) was ≥1 in 32% of patients, <1 in 32% of patients, and unknown in 36% of patients. TMB was high (≥4.5 mut/Mb) in 20 patients and low (<4.5 mut/Mb) in 28 patients.

For the 49 evaluable patients with a median follow-up time of 24 months, the median PFS was 7 months (95% confidence interval [CI], 5.0-8.9 months); median OS was 15 months (95% CI, 11.6-18.4 months). The ORR was 30.6%, including 1 complete response and 14 partial responses; the disease control rate was 87.8% and included 28 patients with stable disease.

The most common all-grade treatment-related adverse events (TRAEs) were leukopenia (98%), neutropenia (92%), and anemia (86%). Grade 3/4 TRAEs included leukopenia (38%), neutropenia (32%), skin rash (6%), anemia (2%), mucositis (2%), and immune-related colitis (2%). Two patients discontinued toripalimab due to AEs (immune-related colitis and skin reaction).

Biomarker analysis found that TP53, KRAS, and CDKN2A genes had the highest mutation frequencies. The presence of SMARCA mutations was associated with shorter PFS (4.2 vs 7.9 months; P = .0029) and OS (10 vs 16 months; P = .069) in patients treated with toripalimab plus chemotherapy.

Exploratory analysis showed that patients with CPS ≥1 had significantly longer PFS compared with CPS <1 (P = .0033); however, median OS was similar in the 2 CPS cohorts (16.1 vs 12.0 months; P = .09). No significant correlation was seen between TMB and PFS.

Based on these results, the researchers concluded that toripalimab combined with gemcitabine plus S-1 had acceptable toxicity and encouraging efficacy in terms of PFS and OS in the first-line treatment of advanced BTCs.

Source: Li W, Wang Y, Yu Y, et al. Toripalimab combined with gemcitabine and S-1 in the first-line treatment of advanced biliary tract cancer. Abstract 4081.

Related Items

GemCis with or without CPI-613 as First-Line Therapy for Patients with Advanced BTCs: The BilT-04 Study
September 2022, Vol 3, No 3
Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy. Gemcitabine/cisplatin (GemCis) is the standard first-line systemic therapy for BTCs; however, median overall survival was only 11.7 months.
Neoadjuvant Gemcitabine/Cisplatin/Nab-Paclitaxel for Resectable High-Risk iCCA: NEO-GAP
September 2022, Vol 3, No 3
For patients with localized intrahepatic cholangiocarcinoma (iCCA), surgical resection holds curative potential for only 30% to 35% of patients due to its high rate of recurrence.
PROs with Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
Results of the randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line chemoimmunotherapy regimen of the PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Regional Subgroup Analysis of Durvalumab plus GemCis in Advanced BTCs: The TOPAZ-1 Study
September 2022, Vol 3, No 3
The randomized, double-blind, global, phase 3 TOPAZ-1 trial demonstrated that the first-line PD-L1 inhibitor durvalumab plus gemcitabine/cisplatin (GemCis; median follow-up, 16.8 months) as first-line treatment significantly improved overall survival (OS) versus placebo plus GemCis (median follow-up, 15.9 months) in patients with advanced biliary tract cancers (BTCs).1
Preservation of Liver Function in Patients with Metastatic iCCA with Extrahepatic Disease
September 2022, Vol 3, No 3
Tumor-related liver failure (TRLF) is the most common cause of death in patients with metastatic intrahepatic cholangiocarcinoma (iCCA), accounting for up to 72% of deaths in patients treated with systemic therapy alone.1
Efficacy and Safety of Futibatinib in iCCA Harboring FGFR2 Fusions/Rearrangements: Updated Results of the FOENIX-CCA2 Trial
September 2022, Vol 3, No 3
Primary analysis of the pivotal, single-arm, phase 2 FOENIX-CCA2 study demonstrated that the FGFR1-4 inhibitor futibatinib as second-line treatment yielded durable objective responses in patients with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusion/rearrangements.
Adjuvant GemCis versus CAP in Patients with Resected Lymph Node–Positive eCCA: The STAMP Study
September 2022, Vol 3, No 3
Adjuvant capecitabine (CAP) is the current standard of care as adjuvant therapy for patients with resected cholangiocarcinoma (CCA); however, patient outcomes are still suboptimal.
CCA Summit Live from ASCO 2022
By Ghassan K. Abou-Alfa, MD, MBA
Videos
Dr Abou-Alfa also provides his perspective on the impact of the data on the management of patients with CCA.
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
September/October 2021, Vol 2, No 3
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.
CCA Summit Live from ASCO 2021
By Mitesh J. Borad, MD
Videos
On June 8, 2021, Dr Mitesh Borad, Associate Professor of Medicine at the Mayo Clinic in Phoenix, AZ, and a member of the Cholangiocarcinoma Summit Program Steering Committee, presented the top 15 abstracts on the management of cholangiocarcinoma and biliary tract cancer at ASCO 2021.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: